Anaveon is a clinical-stage biopharmaceutical company, based in Switzerland, that develops biologics to modulate the function of cytokines and provide substantial therapeutic benefit to cancer patients. Our vision is to develop novel immune therapies benefiting patients suffering from a wide variety of diseases with immune pathology.

Aquinnah Pharmaceuticals is pursuing a novel hypothesis for the treatment of amyotrophic lateral sclerosis, Alzheimer’s disease and other neurodegenerative diseases by developing small molecule therapeutics that target persistent stress granules, a common pathology of neurodegeneration.

Arrakis Therapeutics is pioneering the discovery of small-molecule medicines that directly bind and modify the biological function of RNA to treat disease. This new class of medicines, RNA-targeted small molecules (rSMs), will focus on new disease intervention points identified in the human transcriptome as well as valuable targets that are not accessible with today’s medicines.

Artios Pharma is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The company is building a pipeline of next-generation DDR programs to target hard-to-treat cancers.

Autifony is a UK-based clinical stage biotechnology company deploying its pioneering ion channel drug discovery platform to develop new medicines to treat rare genetic CNS disorders.

Autobahn is a biotechnology company developing a pipeline of transformative small molecule therapies for the treatment of CNS disorders. The company’s lead program leverages a brain-targeting chemistry platform to target the unambiguous link between thyroid hormone and myelin biology. 

BioGraph 55 is developing next-generation B-cell therapies to address major unmet needs in autoimmune disease. Its lead program, B55-001, is a first-in-class bispecific antibody that selectively eliminates disease-driving B cells through a unique mechanism of action. B55-001’s dual co-targeting approach eliminates pathogenic B-cell populations that competitors miss, drives deeper depletion through its unique MoA, and preserves immune function via avidity-driven selectivity – together offering the potential for transformative efficacy across multiple autoimmune indications.

Cartography Biosciences is a company focused on identifying and developing tumor-specific therapeutics, leveraging a unique genomics and computational platform to find targets for immuno-oncology treatments. Their approach analyzes cancers through the lens of antigen expression, aiming to create more precise and effective immunotherapies.

Crossbow Therapeutics, Inc., is a biotechnology company determined to improve the lives of people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies. The company’s T-BoltTM therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets. Crossbow’s efficient and selective approach is designed to target the entire universe of cancer proteins, dramatically expanding the potential of antibody therapy to address many types of cancer.

Curve leverages its proprietary discovery platform to identify functional microcycles that modulate targets within their native intracellular environment. The company is developing a pipeline of cyclic peptide and new small molecule drugs, initially against high priority cancer targets.

DEM Bio is approaching the clinic with an immunomodulatory ADC targeting a novel tumor antigen that is upregulated in GI cancers. The target was uncovered through a proprietary platform investigating myeloid checkpoint signaling via inter-cellular CRISPR screening using tumor cells, primary macrophages, and other innate immune effector cells.

Enara Bio is pioneering the discovery of ‘Dark Antigens’ – a new class of cancer-specific antigens from previously uncharted genomic dark matter. The company is building a pipeline of bispecific T-cell engagers against these novel antigens to improve treatment outcomes for broad populations of cancer patients.

Enlaza’s breakthrough War-LockTM technology enables generation of unique, highly-selective biologic drugs that are engineered to become warheads with the capacity to irreversibly lock to disease related targets. This is accomplished by leveraging their novel synthetic biology platform, coupled with proprietary amino acids, to precision-engineer biological medicines with improved efficacy and safety profiles.

Enodia Therapeutics is a biotechnology company developing potentially best-in-class small molecule therapies to selectively modulate SEC61 translocon to enable the degradation of disease-driving proteins at the point of synthesis before they have a damaging effect. The company’s platform combines a proteomics informed understanding of the secretome with machine-learning–enabled selectivity to support rational drug design. Rooted in pioneering research from the Institut Pasteur and built by Argobio, Enodia is advancing a pipeline initially focused on inflammatory and autoimmune diseases, with additional opportunities across oncology and viral infections enabled by the same underlying biological mechanism.

EvolveImmune is harnessing their “Immunology First” approach to create first-in-category cancer medicines to transform the lives of patients by delivering superior, long-term outcomes compared to current anti-cancer therapies.  They leverage exceptional experience in immunology to swiftly advance our modular, precision biotherapeutics platform to exploit the full potential of the array of unprecedented and validated immuno-oncology targets which comprise our pipeline.

Flare Therapeutics is a biotechnology company changing the paradigm in drugging transcription factors with an initial focus in precision oncology. Flare’s proprietary engine is founded on the identification of novel druggable pockets, or ‘switch sites’, within transcription factor complexes that solve for where to drug and what to optimize for in tuning gene expression to discover small molecule precision medicines for cancer and other diseases.

FoRx Therapeutics is a recently incorporated privately held company aiming to develop first-in-class compounds for cancer treatment.  FoRx focuses on drugging key molecular targets involved in DNA replication stress, as a new approach towards the development of targeted anticancer drugs.

Greywolf Therapeutics is clinical stage company developing a first-of-its-kind approach to antigen modulation. The company’s innovative technology is centered on inhibiting the endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2), which play a central role in the antigen presentation pathway. The company is leveraging its leadership in ERAP inhibition and antigen modulation to advance novel therapeutic approaches to address the source of immune dysfunction in oncology and autoimmunity.

Immunocodex is committed to designing novel tolerogenic mRNA vaccines which re-program immune cells, re-balance the immune system, and restore health in patients suffering from autoimmune diseases. Through the integration of key tolerance-inducing signals alongside disease-specific autoantigens, we engineer effective, targeted therapies for the treatment of disease, while limiting negative systemic side effects.

ImmunOs is leading the next generation of immunotherapies by fast-tracking new discoveries of novel human immunomodulatory proteins that have a role in the innate immune system for cancer treatment.

Indendia Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as many cancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers.

Kestrel Therapeutics leverages a foundation of unique science that employs a physical understanding of the drug-target interaction to build a lead program designed to potently address all KRAS mutations in all tumor types.

Levicept is an asset-centric UK-based biotechnology company developing a novel, safe and efficacious biological therapy, LEVI-04, for the treatment of chronic pain. LEVI-04 has successfully completed a phase II clinical trial in patients with osteoarthritis of the knee.

Mediar is a clinical stage biotechnology company developing therapeutics to halt, or even reverse, fibrosis.  The platform and pipeline are based on an emerging class of novel targets – fibrotic mediators – that play key roles in modulating myofibroblast biology and the development of fibrosis in chronically damaged organs.

MindImmune Therapeutics is a preclinical stage biotech company developing first-in-class drugs that target the immune system to treat CNS diseases. The company is at the forefront of biological advances linking the peripheral immune system to neuroinflammation.

MISSION is discovering and developing first-in-class therapeutics that inhibit disease associated  deubiquitinylase enzymes (DUBs) involved in serious diseases including mitochondrial diseases, neurodegeneration, inflammation, and cancer. The company has built a proprietary world-leading DUB platform that is generating a rich pipeline of potent and selective small molecule drugs.

Montis Biosciences is a biotech company advancing innovative therapeutics to treat chronic inflammation-driven diseases. Montis’ lead program focuses on modulating the multifaceted complement-dependent and -independent roles of C1q, the first mediator of the classical complement. It holds the potential to bring a paradigm shift in the complement field and to revolutionize treatments for certain neurodegenerative diseases and autoimmune neuropathies.

Mozart is a clinical stage company developing CD8 Treg modulators for the treatment of autoimmune and inflammatory diseases. These molecules selectively target the regulatory CD8 T cell network to counteract early events in the autoimmune inflammatory cascade. CD8 Treg Modulators are designed to restore the intrinsic functions of regulatory CD8 T cells to suppress and eliminate pathogenic immune cells, providing durable control of autoimmune and other inflammatory diseases.

National Resilience is a first-of-its-kind manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the medicines of today and tomorrow can be made quickly, safely, and at scale.

Nimbus harnesses the power of computational chemistry, structural biology and AI/ML to design breakthroughs for the treatment of substantial and underserved human diseases. The company’s focus is on metabolic diseases, cancer and immune-inflammatory disorders.

Normunity is developing oncology therapeutics targeting novel proteins that are recruited and repurposed by the tumor to create tumor-specific immunosuppression. In collaboration with the Lieping Chen lab at Yale, the company is generating novel biologics with its lead program, NRM-823, a T cell engager in IND enabling studies, being progressed for the treatment of multiple solid tumors. A target franchise approach includes novel ADC and radiotheranostic programs.

Nucleome Therapeutics is decoding the disease-linked variants located in the non-coding genome to discover first-in-class precision medicine. Nucleome’s platform combines pioneering 3D genome technology and machine learning to shed light on these variants by directly linking genes to diseases and mapping pathways with unprecedented precision for drug discovery for autoimmune diseases.

OTR Therapeutics is dedicated to transforming early-stage innovations into globally impactful therapies for critical diseases with high unmet medical needs. With a strategic focus on oncology, immunology and inflammation (I&I), and cardiovascular and metabolic (CVM) diseases, the company identifies and acquires distinctive assets from preclinical to early clinical stages, accelerating their development into differentiated, globally relevant treatments.

Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glycoimmune Checkpoint inhibitors to treat cancer. The company’s proprietary platform integrates technologies and insights from Nobel laureate Carolyn Bertozzi to create a novel approach to treating cancer.

PrescriberPoint is transforming the way pharmaceutical companies interact with healthcare providers. The company is creating a digital marketplace based on a “pull” vs. “push” model where healthcare providers can access all the support they need from Pharmacos on their terms, industry-wide, in one place including access to product information, samples, rep and MSL support and patient assistance programs

ReCode is a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform enables highly precise and targeted delivery of genetic medicines directly to the organs, tissues, and cells implicated in disease. ReCode’s lead programs are inhaled disease-modifying mRNA-based therapies formulated with the SORT LNP delivery platform for the rare pulmonary diseases of primary ciliary dyskinesia (PCD) and cystic fibrosis (CF).

RefleXion Medical develops and commercializes SCINTIX biology-guided radiotherapy, a groundbreaking treatment that uses a single radiotracer injection to transform cancer cells into real-time biological beacons to control external-beam radiotherapy delivery to single or multiple tumors. SCINTIX therapy is indicated for use in FDG-guided treatment of lung and bone tumors and is being studied for broader indications. In addition, the company offers the RefleXion® X1 system for conventional radiotherapy for all solid tumors located anywhere in the body.

Saama is an AI-driven Intelligent Clinical Cloud company, enabling the life sciences industry to conduct faster and safer clinical development and regulatory programs.  Their Life Science Analytics Cloud (LSAC) platform is used by many biopharmaceutical companies on thousands of studies.   LSAC’s rich applications facilitate an unprecedented, authoritative oversight of comprehensive clinical research data, enabling companies to file New Drug Applications (NDAs) more efficiently and bring drugs to market faster. 

Storm Therapeutics is a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RME) for oncology and other diseases.

Strata Oncology is a precision oncology company aiming to enable large-scale molecularly informed clinical cancer research.  The company has developed an end-to-end technology platform for sequencing tumors across a network of health systems and has used AI to build algorithms to determine the best course of therapy for patience on an individual level.

TRex Bio is a discovery-stage biotechnology company focused on making a meaningful difference in the lives of patients suffering from fatal or debilitating illnesses including autoimmune and inflammatory diseases. TRex aims to achieve this vision via functional manipulation of Tregs and other immune cells in a tissue-specific and disease-specific fashion.

Triana Biomedicines is developing molecular glue therapeutics initially tailored for targeted protein degradation applications. TRIANA is building its pipeline using a target-first, rational approach to molecular glue discovery, and aspires to develop products for a wide range of therapeutic applications.

Trimtech Therapeutics is developing selective small molecule degraders of toxic protein aggregates for treatment of neurodegenerative and peripheral diseases, while leaving functional monomers untouched. The company’s proprietary degrader technology leverages TRIM21 biology as pioneered by the company’s founders Dr Leo James and Dr Will McEwan from the University of Cambridge.

Vibrant Therapeutics is a clinical-stage biotechnology company developing intelligent, logic-gated therapeutics designed to selectively activate in the desired disease microenvironment. Leveraging an integrated computational and experimental (“dry-wet”) R&D platform, the company is advancing a pipeline of innovative first-in-class/best-in-class programs, including masked T-cell engagers for solid tumors, and exploring broader applications of its technology across additional modalities and therapeutic areas.

VitaDAO is a decentralized accelerator for drug development. The core mission is the acceleration of research and development in the longevity space.